Your browser doesn't support javascript.
loading
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
Maldonado-Pérez, Noelia; Tristán-Manzano, María; Justicia-Lirio, Pedro; Martínez-Planes, Elena; Muñoz, Pilar; Pavlovic, Kristina; Cortijo-Gutiérrez, Marina; Blanco-Benítez, Carlos; Castella, María; Juan, Manel; Wenes, Mathias; Romero, Pedro; Molina-Estévez, Francisco J; Marañón, Concepción; Herrera, Concha; Benabdellah, Karim; Martin, Francisco.
Afiliação
  • Maldonado-Pérez N; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Tristán-Manzano M; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Justicia-Lirio P; LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Martínez-Planes E; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Muñoz P; LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Pavlovic K; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Cortijo-Gutiérrez M; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Blanco-Benítez C; Department of Celular Biology, Faculty of Sciences, University of Granada, Granada, Spain.
  • Castella M; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Juan M; Cellular Therapy Unit, Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.
  • Wenes M; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Romero P; Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Molina-Estévez FJ; LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.
  • Marañón C; Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Herrera C; Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Benabdellah K; Department of Oncology, University of Lausanne, Épalinges, Switzerland.
  • Martin F; Department of Oncology, University of Lausanne, Épalinges, Switzerland.
Front Immunol ; 13: 1011858, 2022.
Article em En | MEDLINE | ID: mdl-36275777

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
...